SCHEMBL10187308

SCHEMBL10187308

CCOc1ccc(N)c(OCC)n1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.41
MAPK1 P28482 2/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
MAPT P10636 2/20 0.41
HPGD P15428 2/20 0.41
KDM4E B2RXH2 1/20 0.41
POLB P06746 1/20 0.41
HSD17B10 Q99714 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
NPC1 O15118 2/20 0.40
RAB9A P51151 1/20 0.40
APOBEC3G Q9HC16 1/20 0.38
TSHR P16473 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
PIK3CD O00329 1/20 0.37
PIK3CA P42336 1/20 0.37
PIK3CB P42338 1/20 0.37
PI4KA P42356 1/20 0.37
PIK3CG P48736 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21582525 0.89 MAPT (0.39) ALDH1A1MAPK1MEN1KMT2AMAPT
SCHEMBL30271360 0.83 ALDH1A1 (0.35) ALDH1A1MAPK1MEN1KMT2AMAPT
SCHEMBL12113205 0.83 PIK3CD (0.35) ALDH1A1MAPK1MEN1KMT2AMAPT
SCHEMBL2955940 0.82 ALDH1A1 (0.42) ALDH1A1MAPK1MEN1KMT2AMAPT
SCHEMBL23458719 0.80 HSD17B10 (0.41) ALDH1A1MAPK1MEN1KMT2AMAPT
SCHEMBL12113611 0.80 ALDH1A1 (0.41) ALDH1A1MAPK1MEN1KMT2AMAPT
SCHEMBL29982955 0.80 HSD17B10 (0.41) ALDH1A1MAPK1MEN1KMT2AMAPT
SCHEMBL26329035 0.79 CYP1A2 (0.49) ALDH1A1MAPK1MEN1KMT2AMAPT
SCHEMBL11803401 0.78 KDM4E (0.41) ALDH1A1MAPK1MEN1KMT2AMAPT
SCHEMBL12520557 0.78 ALDH1A1 (0.40) ALDH1A1MAPK1MEN1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2012001107-A1 PIPERIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-01-05 WO disclosed